Hologic Chairman, CEO Steve MacMillan to Step Down When Takeover Closes
By Robb M. Stewart
Hologic's longtime chairman, president and chief executive, Steve MacMillan, plans to retire when the medical-technology company's takeover by Blackstone and TPG is finalized.
The company said all required regulatory approvals for the planned transaction have now been received, and that the deal is set to close on or about Tuesday.
Marlborough, Mass.-based Hologic said its next chief executive is expected to be announced when the transaction closes.
Hologic in October agreed a deal that would see Blackstone and TPG buy it for as much as $18.3 billion, including debt. Shareholders are set to receive $76 a share in cash as part of a transaction that also includes a nontradable contingent value right to receive up to $3 a share in two payments of up to $1.50 each, for total consideration of up to $79 a share.
MacMillan, 62 years old, joined Hologic as president and CEO at the end of 2013. He was elected chairman in 2015. From 2005 to 2012, he was president and CEO of Stryker, where he had been president since 2003. Before that, he was a senior executive at Pharmacia and Johnson & Johnson. He began his career at Procter and Gamble in 1985.
Write to Robb M. Stewart at robb.stewart@wsj.com
(END) Dow Jones Newswires
April 06, 2026 08:45 ET (12:45 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
4 Stocks to Buy Before They Rise Further
2 Undervalued Stocks to Buy Before They Rebound
The 10 Best Dividend Stocks
12 Best Blue-Chip Stocks to Buy for the Long Term
United States